On June 12, 2025, during Spero Therapeutics, Inc.'s Annual Meeting, stockholders approved increasing the shares authorized under the 2017 Stock Incentive Plan by 3 million shares, re-elected directors, and ratified PricewaterhouseCoopers as their external auditors.